1 / 10

Faculty

National GI Tumor Board Clinical Investigators Provide Their Perspectives on Current Cases of Gastrointestinal Cancer Friday, January 21, 2011 7:00 PM – 9:30 PM San Francisco, California. Moderator Neil Love, MD. Faculty. Charles D Blanke, MD David Cunningham, MD Steven A Curley, MD.

cybele
Download Presentation

Faculty

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. National GI Tumor BoardClinical Investigators Provide Their Perspectives on Current Cases of Gastrointestinal CancerFriday, January 21, 20117:00 PM – 9:30 PMSan Francisco, California ModeratorNeil Love, MD Faculty Charles D Blanke, MD David Cunningham, MD Steven A Curley, MD Eileen M O’Reilly, MD Eric Van Cutsem, MD, PhD Andrew X Zhu, MD, PhD

  2. Case presented by Dr Schwartz 76 yo man: PMH – NIDDM and CAD 7/10: New anemia with melanotic stool  Endoscopy = tumor from distal esophagus to gastric cardia Biopsy = PD adenoCA, HER2 IHC 1+ (FISH-negative) PET/CT = GE tumor uptake + non-bulky mediastinal nodes and ? liver lesion Patient refused surgery 9/10: Cis/irinotecan  GI bleeding resolved and ~ CT response  completed XRT + wkly cis/irinotecan (11/10) Follow up endoscopy/scans pending

  3. Case presented by Dr Schwartz 76 yo man: PMH – NIDDM and CAD 7/10: New anemia with melanotic stool  Endoscopy = tumor from distal esophagus to gastric cardia Biopsy = PD adenoCA, HER2 IHC 1+ (FISH-negative) PET/CT = GE tumor uptake + non-bulky mediastinal nodes and ? Liver lesion Patient refused surgery 9/10: Cis/irinotecan  GI bleeding resolved and ~ CT response  completed XRT + wkly cis/irinotecan (11/10) Follow up endoscopy/scans pending

  4. National GI Tumor BoardClinical Investigators Provide Their Perspectives on Current Cases of Gastrointestinal CancerFriday, January 21, 20117:00 PM – 9:30 PMSan Francisco, California ModeratorNeil Love, MD Faculty Charles D Blanke, MD David Cunningham, MD Steven A Curley, MD Eileen M O’Reilly, MD Eric Van Cutsem, MD, PhD Andrew X Zhu, MD, PhD

  5. HER2 Diagnostics in Gastric Cancer — Guideline Validation and Development of Standardized Immunohistochemical Testing Rüschoff J et al. Virchows Arch 2010;457:299-307 Assessment of a HER2 Scoring System for Gastric Cancer: Results from a Validation Study Hofmann M et al. Histopathology 2008;52:797-805

  6. Comparison of HER2 IHC Slide Scoring in Gastric/GEJ and Breast Cancers Marked Heterogeneity of HER2 Immunostaining Incomplete Staining With Loss of Apical Membrane HER2 Expression Continuous Complete 360 Degree Membranous HER2 Staining Gastroesophageal Junction Cancer Breast Cancer Gastric Cancer Courtesy of Jeffrey S Ross, MD

  7. ToGA: HER2 Status of Enrolled Patients FISH positive/IHC 2+ FISH positive/IHC 1+ FISH positive/IHC 0 FISH no result/IHC 3+ FISH positive/IHC no result FISH positive/IHC 3+ FISH negative/IHC 3+ Bang YJ et al. Lancet 2010;376(9742):687-97.

  8. Case presented by Dr Schwartz 76 yo man: PMH – NIDDM and CAD 7/10: New anemia with melanotic stool  Endoscopy = tumor from distal esophagus to gastric cardia Biopsy = PD adenoCA, HER2 IHC 1+ (FISH-negative) PET/CT = GE tumor uptake + non-bulky mediastinal nodes and ? Liver lesion Patient refused surgery 9/10: Cis/irinotecan  GI bleeding resolved and ~ CT response  completed XRT + wkly cis/irinotecan (11/10) Follow up endoscopy/scans pending

More Related